|
|
Volumn 269, Issue 5224, 1995, Pages 696-699
|
|
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIVIRUS AGENT;
LAMIVUDINE;
RNA DIRECTED DNA POLYMERASE;
VALINE;
VIRUS RNA;
ZIDOVUDINE;
ANTIVIRAL ACTIVITY;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
DRUG EFFICACY;
DRUG RESISTANCE;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS 1;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
MAJOR CLINICAL STUDY;
MULTICENTER STUDY;
NONHUMAN;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
RETROVIRUS;
VIRUS MUTANT;
ANTIVIRAL AGENTS;
BASE SEQUENCE;
CD4 LYMPHOCYTE COUNT;
CELL LINE;
CODON;
DRUG RESISTANCE, MICROBIAL;
DRUG THERAPY, COMBINATION;
HELA CELLS;
HIV INFECTIONS;
HIV-1;
HIV-1 REVERSE TRANSCRIPTASE;
HUMANS;
LAMIVUDINE;
MOLECULAR SEQUENCE DATA;
MUTAGENESIS, SITE-DIRECTED;
POINT MUTATION;
REVERSE TRANSCRIPTASE INHIBITORS;
RNA, VIRAL;
RNA-DIRECTED DNA POLYMERASE;
SERIAL PASSAGE;
ZALCITABINE;
ZIDOVUDINE;
HUMAN IMMUNODEFICIENCY VIRUS;
HUMAN IMMUNODEFICIENCY VIRUS 1;
UNIDENTIFIED RETROVIRUS;
|
|
EID: 0029028067
PISSN: 00368075
EISSN: None
Source Type: Journal
DOI: 10.1126/science.7542804 Document Type: Article |
|
Times cited : (627)
|
|
References (28)
|
